By Associate Professor Megan Amanda Crumbaker

Journal articles

Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Zheng A; Khan S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L, 2024, 'Comparison of Posttherapy 4- and 24-Hour [¹⁷⁷Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65, pp. 1939 - 1944, http://dx.doi.org/10.2967/jnumed.124.267606

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of ⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on ⁶⁸Ga-PSMA-11 PET/CT', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65, pp. 1371 - 1375, http://dx.doi.org/10.2967/jnumed.124.267881

Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L, 2024, 'Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to ¹⁷⁷Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65, pp. 904 - 908, http://dx.doi.org/10.2967/jnumed.123.267014

Kumar S; Crumbaker M; Emmett L, 2024, '“Unraveling the Hypocalcemic Response to ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy,”', Journal of Nuclear Medicine, 65, pp. 333 - 334, http://dx.doi.org/10.2967/jnumed.123.266768

Hall A; Crumbaker M; Pham J; Liu JJ; Sim H-W; Joshua AM, 2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', Journal of Clinical Oncology, 42, pp. 4 - 4, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.4

Gupta M; Wells C; Regan MM; Xie W; Navani V; Saliby RM; Basappa NS; Donskov F; Yuasa T; Takemura KN; Kollmannsberger CK; Crumbaker M; Lalani A-KA; Powles T; Pal SK; McKay RR; Lee J-L; Kanesvaran R; Choueiri TK; Heng DYC, 2024, 'Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.', Journal of Clinical Oncology, 42, pp. 390 - 390, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.390

Tolmeijer SH; Kwan EM; Ng SWS; Joshua A; Emmett L; Crumbaker M; Hamid AA; Anton A; Horvath LG; Chan J; Bressel M; Buteau JP; Dhiantravan N; Ayati N; Keerthikumar S; Goode D; Hicks R; Hofman MS; Wyatt AW; Sandhu SK, 2024, '1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)', Annals of Oncology, 35, pp. S975 - S976, http://dx.doi.org/10.1016/j.annonc.2024.08.1697

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007

Kumar S; Crumbaker M; Harvey C; Pathmanandavel S; John N; Swiha MM; McDonald MM; Clifton-Bligh R; Lee A; Bastick P; Counter W; Nguyen A; Emmett L, 2023, 'The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy', Journal of Nuclear Medicine, 64, pp. 1412 - 1416, http://dx.doi.org/10.2967/jnumed.123.265759

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064

Conduit C; Mak B; Qu W; Yeung T; Bressel M; Cusick T; Dhillon HM; De Abreu Lourenço R; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Sewak S; Chau NMH; Allen R; Davis ID; Clark SJ; Horvath L; Mahon KL, 2023, 'GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).', Journal of Clinical Oncology, 41, pp. TPS5099 - TPS5099, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps5099

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005

Pemberton L; Allen C; Handel E; Weickhardt AJ; Tran B; Crumbaker M; Shapiro JD; Risbridger GP; Pook DW, 2023, 'Carboplatin in metastatic castrate resistant prostate cancer: A retrospective study of heavily pretreated patients (COMPACT).', Journal of Clinical Oncology, 41, pp. 158 - 158, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.158

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of ¹⁷⁷Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective ¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing ¹⁷⁷Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Sharma S; Agrawal S; Poole A; Hovey E; Pranavan G; Gedye C; Mallesara G; Guminski A; Lee A; Stockler MR; Hickey A; Eu P; Joshua AM; Crumbaker M; Nguyen A, 2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231156392

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Goode D; Keerthikumar S; Gupta S; Joshua AM; Emmett L; Crumbaker M; Singer T; Lam E; Fernandez L; Jimenez E; Zhang D; Lin Y; Wenstrup RJ; PASAM A; Hicks R; Kong G; Hamid A; Sandhu SK, 2023, '1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 34, pp. S988 - S989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JCH; Pattison DA; Tan H; Kirkwood ID; Sandhu SK; Nguyen A; Gedye C; Rutherford N; Hofman M; Martin A; Stockler MR; Davis ID, 2023, 'LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)', Annals of Oncology, 34, pp. S1325 - S1325, http://dx.doi.org/10.1016/j.annonc.2023.10.086

Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG, 2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, http://dx.doi.org/10.1186/s12916-022-02298-0

Chen S; Petricca J; Ye W; Guan J; Zeng Y; Cheng N; Gong L; Shen SY; Hua JT; Crumbaker M; Fraser M; Liu S; Bratman SV; van der Kwast T; Pugh T; Joshua AM; De Carvalho DD; Chi KN; Awadalla P; Ji G; Feng F; Wyatt AW; He HH, 2022, 'The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-34012-2

Joshua AM; Armstrong A; Crumbaker M; Scher HI; de Bono J; Tombal B; Hussain M; Sternberg CN; Gillessen S; Carles J; Fizazi K; Lin P; Duggan W; Sugg J; Russell D; Beer TM, 2022, 'Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER', European Journal of Cancer, 170, pp. 285 - 295, http://dx.doi.org/10.1016/j.ejca.2022.04.005

Chan DL; Pavlakis N; Crumbaker M; Lawrence B; Barber C; Price TJ; Michael M; Oberg K, 2022, 'Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series', Asia-Pacific Journal of Clinical Oncology, 18, pp. 209 - 216, http://dx.doi.org/10.1111/ajco.13577

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '¹⁷⁷Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552

Conduit C; Mak B; Qu W; Lulio JD; Burder R; Bressel M; Cusick T; Dhillon HM; Lourenço RDA; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Allen R; Davis ID; Clark SJ; Horvath LG; Mahon KL, 2022, 'GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221092486

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden AJ; Brooks A; Patel MI; Lau H; Woo H; Bariol S; Gurney H, 2022, 'Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center', Asia-Pacific Journal of Clinical Oncology, 18, pp. e23 - e31, http://dx.doi.org/10.1111/ajco.13548

Joshua AM; Gurney H; Dhillon HM; Crumbaker M, 2022, 'Patient Preference or Indifference: Learning from the CABADOC Study', European Urology, 81, pp. 241 - 242, http://dx.doi.org/10.1016/j.eururo.2021.11.005

Nguyen LT; Lo CS; Fyrsta M; Nie J; Yam JY; Yen PH; Le MX; Hersey K; Kenk M; Crumbaker M; Fleshner N; Kulkarni G; Hamilton R; Jewett M; Finelli A; Evans A; Sweet J; Ohashi PS; Joshua AM, 2022, 'Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue', Prostate Cancer, 2022, http://dx.doi.org/10.1155/2022/6499344

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of ¹⁷⁷Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European urology oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID, 2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491

Lin HM; Mak B; Yeung N; Huynh K; Meikle TG; Mellett NA; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Crumbaker M; Stricker PD; Du P; Yu J; Jia S; Scheinberg T; Fitzpatrick M; Bonnitcha P; Sullivan DR; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', EBioMedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625

Lin HM; Yeung N; Hastings JF; Croucher DR; Huynh K; Meikle TG; Mellett NA; Kwan EM; Davis ID; Tran B; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Bastick P; Crumbaker ML; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, http://dx.doi.org/10.3390/cancers13194964

Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LJK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA, 2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, 10, http://dx.doi.org/10.21037/tau-20-1444

Bhatnagar A; McKay MJ; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2020, 'Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma', Journal of Mass Spectrometry, 55, http://dx.doi.org/10.1002/jms.4584

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557

Crumbaker M; Chan EKF; Gong T; Corcoran N; Jaratlerdsiri W; Lyons RJ; Haynes AM; Kulidjian AA; Kalsbeek AMF; Petersen DC; Stricker PD; Jamieson CAM; Croucher PI; Hovens CM; Joshua AM; Hayes VM, 2020, 'The impact of whole genome data on therapeutic decision‐making in metastatic prostate cancer: A retrospective analysis', Cancers, 12, http://dx.doi.org/10.3390/cancers12051178

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Quah GT; Espinoza D; Arasaratnam M; Crumbaker M; Balakrishnar B; Brooks A; Lau H; Patel M; Bariol S; Gurney H, 2020, '212P Stage I non-seminoma testicular cancer: Adjuvant management and outcomes', Annals of Oncology, 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.223

Quah GT; Espinoza D; Crumbaker M; Balakrishnar B; Arasaratnam M; Bariol S; Brooks A; Lau H; Patel M; Gurney H, 2020, '213P Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance', Annals of Oncology, 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.224

Bhatnagar A; McKay MJ; Thaysen-Andersen M; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2019, 'Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1126-1127, http://dx.doi.org/10.1016/j.jchromb.2019.121741

Crumbaker M; Wong J; Joshua AM; Spigelman AD, 2019, 'Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center', Asia-Pacific Journal of Clinical Oncology, 15, pp. 257 - 261, http://dx.doi.org/10.1111/ajco.13148

Arasaratnam M; Crumbaker M; Bhatnagar A; McKay MJ; Molloy MP; Gurney H, 2019, 'Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer', Cancer Chemotherapy and Pharmacology, 84, pp. 139 - 146, http://dx.doi.org/10.1007/s00280-019-03862-x

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to ¹⁷⁷lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial ⁶⁸Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP, 2018, 'Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry', Journal of Pharmaceutical and Biomedical Analysis, 154, pp. 66 - 74, http://dx.doi.org/10.1016/j.jpba.2018.03.012

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden A; Brooks A; Patel M; Gurney H, 2018, 'Patterns of care and outcome of germ cell tumours (GCT) in an Australian high-volume centre.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e16534

Crumbaker M; Savdie R; Joshua AM, 2018, 'Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer', European Urology, 73, pp. 736 - 737, http://dx.doi.org/10.1016/j.eururo.2017.11.005

Crumbaker M; Guminski A; Gurney H; Sabanathan D; Wong S; Pavlakis N, 2018, 'Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia', Asia-Pacific Journal of Clinical Oncology, 14, pp. e45 - e49, http://dx.doi.org/10.1111/ajco.12686

Crumbaker M; Gurney H, 2017, 'Dose considerations for anti-cancer drugs in metastatic prostate cancer', Prostate, 77, pp. 1199 - 1204, http://dx.doi.org/10.1002/pros.23378

Back to profile page